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Summary
The Kaposi’s sarcoma herpesvirus (KSHV) has been identified as the etiologic agent of Kaposi’s sarcoma (KS), but initial
events leading to KS development remain unclear. Characterization of the KSHV genome reveals the presence of numerous
potential oncogenes. To address their contribution to the initiation of the endothelial cell-derived KS tumor, we developed
a novel transgenic mouse that enabled endothelial cell-specific infection in vivo using virus expressing candidate KSHV
oncogenes. Here we show that transduction of one gene, vGPCR, was sufficient to induce angioproliferative tumors that
strikingly resembled human KS. Endothelial cells expressing vGPCR were further able to promote tumor formation by
cells expressing KSHV latent genes, suggestive of a cooperative role among viral genes in the promotion of Kaposi’s
sarcomagenesis.
Introduction KS is a multifocal neovascular tumor characterized histologi-
cally by proliferating spindle cells, angiogenesis, erythrocyte-
replete vascular slits, profuse edema, and a variable inflamma-Kaposi’s sarcoma (KS) is an AIDS-defining illness and remains
tory cell infiltrate. The dominant cell of KS lesions, the spindlethe most frequent tumor arising in HIV-infected patients (Boshoff
cell, elaborates a variety of proinflammatory and angiogenicand Chang, 2001; Moore and Chang, 2001). The clinical course
factors and is considered the driving force in KS lesions (Ganem,of AIDS-related KS is variable, ranging from minimal stable dis-
1997). The origin of the spindle cell remains unclear. Althoughease to explosive growth, often involving the skin, oral mucosa,
believed to be of endothelial origin, its precise histogenesis, aslymph nodes, and visceral organs, including the gastrointestinal
well as the early events surrounding the initiation of the KStract, lung, liver, and spleen. Indeed, KS has recently emerged
tumor, are still poorly understood (Flore et al., 1998; Ganem,as one of the most common neoplasms among children and
adult men in the developing world, and represents a significant 1997; Jenner and Boshoff, 2002). The recent discovery of the
Kaposi’s sarcoma associated herpesvirus (KSHV or HHV-8) hascause of morbidity and mortality among the AIDS population
(Mitsuyasu, 2000). Unfortunately, clinical management of KS invigorated renewed interest in this enigmatic disease (Chang
et al., 1994). This novel -herpesvirus is associated with allhas proven to be challenging. Today, despite extensive investi-
gation into its molecular etiology, KS remains an incurable dis- forms of KS (classic, iatrogenic, endemic, and AIDS-related),
in addition to two other neoplastic disorders: primary effusionease (Hermans, 2000; Mitsuyasu, 2000).
S I G N I F I C A N C E
The study of Kaposi’s sarcoma has been limited by the difficulty of passaging KSHV in vitro and the lack of appropriate animal
models to study KS in vivo. To overcome these obstacles, we developed and characterized a mouse model system that mimics the
infectious process by which KSHV targets endothelial cells in vivo, recapitulating the initiation of Kaposi’s sarcomagenesis. Here we
demonstrate a critical role for vGPCR in initiating KS tumor development. We also show that endothelial cells expressing vGPCR
cooperate with cells expressing KSHV latent genes, promoting their tumorigenic potential through a paracrine mechanism. This
animal model thus provides fundamental insight into the pathogenesis of KSHV and will be uniquely suited to further study the
molecular events defining Kaposi’s sarcoma.
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lymphoma (PEL) and multicentric Castleman’s disease (MCD). in all tissues examined of TIE2-tva transgenic but not wild-type
mice (Figure 1A and data not shown). Moreover, all endothelialOf note, infection of primary human endothelial cells with puri-
fied KSHV induced cell transformation (Flore et al., 1998). How- cells expressing TVA also expressed 31 integrin (Figure 1B),
the cellular receptor for KSHV (Akula et al., 2002), suggestingever, further investigation revealed that the KSHV genome was
present in only a subset of the transformed cells. These in that the TVA-expressing cells in the TIE2-tva mouse correspond
to those naturally targeted by KSHV.vitro results correlate with what is observed in early human KS
lesions, in which only a small percentage (10%) of endothelial To examine whether TVA-expressing endothelial cells were
susceptible to ALV-derived viral infection in vivo, we tested virusand spindle cells are infected by KSHV (Dupin et al., 1999).
These intriguing observations also suggest the involvement of expressing the polyoma middle T antigen (PyMT), which induces
multifocal hemorrhages and benign endotheliomas when ex-a paracrine mechanism in KSHV sarcomagenesis.
Inspection of the KSHV genome reveals several candidate pressed in animals by retroviral transduction (Ong et al., 2001;
Williams et al., 1988). PyMT protein could be detected in chickengenes that bear potential for oncogenesis (Gruffat et al., 2000).
Unfortunately, transmission of KSHV in vitro has met with limited fibroblasts (DF-1) (Himly et al., 1998; Schaefer-Klein et al., 1998)
transfected with the subgroup A avian leukosis virus-derivedsuccess and, therefore, analysis of genomic deletion mutants
is currently not feasible. The identification of potential KSHV cloning vector (RCASBP[A]) (Hughes et al., 1987) carrying PyMT
(RCAS-PyMT) (Figure 2A). Infection with the viral supernatantoncogenes has relied primarily on their overexpression. A major
caveat to these studies is that these genes are examined in collected from RCAS-PyMT DF-1 producer cells resulted in ex-
pression of PyMT in immortalized murine endothelial cellsvitro in cells that may not represent the natural target for KSHV
infection; the results must therefore be interpreted cautiously. (SVECs) ectopically expressing TVA (EC-TVA) (Figure 2A). As
expected, parental SVECs were resistant to viral infection (Fig-To overcome current obstacles in examining the oncogenic
potential of KSHV in endothelial cells in vivo, we engineered a ure 2A), confirming the specificity of this method of gene delivery
to TVA expressing cells. We next infected litters resulting fromtransgenic mouse line expressing the avian leukosis virus (ALV)
receptor, TVA (Bates et al., 1993; Young et al., 1993), under the the breeding of TIE2-tva heterozygous animals to FVB/N mice,
5 days after birth, by intraperitoneal (IP) injection of RCAS-PyMTcontrol of the vascular endothelial cell-specific TIE2 promoter
(Schlaeger et al., 1997). Only mammalian cells engineered to virus (107 IU). Surprisingly, 50% of all injected animals died 9–17
days after injection. Genotyping of infected offspring revealedexpress the tva transgene can be transduced by infection with
ALV, thus enabling the somatic introduction of multiple genes that no animals carrying the tva transgene survived (Figure 2B).
Conversely, none of the wild-type-littermate controls exhibitedin vivo, in a tissue-specific manner (Federspiel et al., 1994;
Fisher et al., 1999; Orsulic et al., 2002). Using this model, we any gross alteration or died, even when observed up to 12
months following injection (Figure 2B). Histological inspectionthen examined the ability of individual KSHV genes to initiate
KS development using ALV-derived recombinant retroviruses of TIE2-tva mice sacrificed ten days after infection with RCAS-
PyMT revealed massive multifocal hemorrhages in all tissuesencoding candidate KSHV oncogenes. Despite prior studies
suggesting that several latent genes—believed to be critical for examined (Figure 2C), likely secondary to loss of vascular integ-
rity in association with endothelial hyperproliferation (WilliamsKS progression—harbor transforming potential in vitro (Jenner
and Boshoff, 2002), these genes do not appear to be sufficient et al., 1988). This potent biological activity was dose dependent,
and as little as 103 IU were sufficient to cause the death ofto initiate endothelial cell transformation in vivo in our mouse
model. However, inclusion of additional genes also suspected 25% of the TIE2-tva injected mice (Figure 2B). These animals
developed multiple benign hemangiomas composed of well-of playing a critical role in spindle cell growth and survival re-
vealed that one gene, the constitutively active KSHV G protein- differentiated endothelial cells (results not shown), further sup-
porting the specificity of the targeted cell type. Tissue examina-coupled receptor (vGPCR), when injected in isolation, potently
induced Kaposi-like lesions in TIE2-tva mice. These tumors tion of littermate controls or TIE2-tva mice infected with RCAS-
AP or RCAS--lactamase virus revealed no pathology up to 18strikingly resembled human KS and expressed key histopatho-
logical and molecular hallmarks for this disease. Remarkably, months following infection (results not shown). These results
suggested that the TIE2-tva mouse represents a suitable animalendothelial cells expressing vGPCR were further able to pro-
mote the tumorigenic potential of cells expressing latent KSHV model to test the ability of transforming sequences to promote
hyperproliferation of endothelial cells after retroviral transduc-genes through a paracrine mechanism. These findings implicate
vGPCR in both the initiation and promotion of KS tumor develop- tion in vivo.
ment and further suggest that this viral G protein-coupled recep-
tor may be a key target in the development of pathogenesis- Delivery of KSHV oncogenes to TIE2-tva mice
We next set out to determine which KSHV oncogenes couldbased therapies against KSHV.
initiate endothelial cell transformation in TIE2-tva mice by engi-
neering avian retroviruses carrying putative KSHV latent trans-Results
forming or survival genes. Latent genes are expressed in almost
all spindle cells in late KS lesions, and are therefore predictedCharacterization of TIE2-tva transgenic mice
To study the role of KSHV-encoded oncogenes in KS pathogen- to play a critical role in the progression of Kaposi’s sarcomagen-
esis (Jenner and Boshoff, 2002). Indeed, two KSHV latent genesesis in vivo, we developed a TVA-based retroviral gene transfer
system to specifically express candidate KSHV oncogenes in (vFlip and Kaposin) have been previously reported to harbor
transforming potential in vitro (Djerbi et al., 1999; Muralidhar etmouse endothelial cells. We engineered transgenic mice to ex-
press the avian retroviral receptor, TVA, under the control of al., 1998). To determine their capacity to initiate KS tumorigene-
sis in vivo, we prepared avian retrovirus encoding the latentthe vascular endothelial cell-specific TIE2 promoter. Expression
of this receptor was exclusively detectable in endothelial cells genes vCyclin, vFlip, or Kaposin. Additionally, as two other
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Figure 1. Coexpression of the receptor for the avian leukosis virus, TVA, and the KSHV cellular receptor, 31 integrin, in endothelial cells of TIE2-tva transgenic
mice
A: Immunohistochemical detection of TVA in endothelial cells, using the TVA antibody. Staining of TVA correlates with endothelial-specific staining of blood
vessels for CD31 (PECAM-1), in the brain and heart of TIE2-tva (tva) mice, but it is absent in control (wt) animals.
B: Immunohistochemical staining of a liver of a TIE2-tva mouse with CD31 (PECAM-1), TVA, and 3 integrin antibodies, respectively. Endothelial cells of TIE2-
tva mouse, stained with CD31 specific antibody, coexpress both TVA and the cellular receptor for KSHV, 31 integrin. Scale bar 100 m.
KSHV-encoded latent genes, LANA-1 and LANA-2 (in addition over, vCyclin induction of H1 phosphorylation (Godden-Kent et
al., 1997), vFlip activation of the B responsive element (Liu etto three other KSHV encoded genes, vIRF1, K8, and ORF50),
have been previously suggested to act by inhibiting the tumor al., 2002), Kaposin activation of MAPK (Kliche et al., 2001), and
p53mutV135A inhibition of p53 transcriptional activity (Harveysuppressor p53 (Friborg et al., 1999; Rivas et al., 2001), we also
generated a retrovirus encoding its potent dominant negative et al., 1995) were all verified in cultured cells to ensure that all
viral constructs encoded biologically active proteins (notmutant, p53mutV135A (Harvey et al., 1995). Prior to introducing
these viral constructs into animals, they were first tested in shown). Surprisingly, although several of the latent genes were
predicted to play an important role in driving Kaposi’s sarco-cell culture to ensure the appropriate expression and biological
activity of the respective gene products. The corresponding magenesis, when injected in isolation, none affected mouse
survival (Figure 3B). Furthermore, mice injected with virus en-encoded proteins of all ALV-derived viral constructs were readily
detected by immunoblotting of DF-1 transfected cells (Figure coding both vCyclin and vFlip, using a bicistronic construct
(Low et al., 2001) (Figure 3A), similarly failed to manifest any3A), and by immunofluorescence in EC-TVA infected cells (Fig-
ure 3B). The precise subcellular localization of all proteins phenotype up to one year following injection (Figure 3B). These
results raised the possibility that the KSHV gene responsible(plasma membrane (PyMT), perinuclear (vCyclin and vFlip), Golgi
membrane (Kaposin), and cytoplasm and nucleus (p53mutV135A) for the initiation of Kaposi’s sarcomagenesis may not be a latent
gene.were also verified by immunofluorescence in EC-TVA cells (Fig-
ure 3B) and in transfected 293T cells (results not shown). More- We therefore expanded our study to include additional
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Figure 2. Infection with virus encoding polyoma middle T antigen (PyMT) induces multifocal hemorrhages in TIE2-tva mice
A: TVA-expressing cells are permissive to retroviral infection by avian leukosis virus-derived vector (RCAS) encoding PyMT. AU5 tagged PyMT was detected
by immunofluorescence in chicken fibroblasts (DF-1), EC-TVA, but not in SVEC after infection with RCAS-PyMT virus.
B: Surviving mice (%) after intraperitoneal infection with RCAS-PyMT virus. Five-day-old mice born from TIE2-tva  FVB/N breeding pairs were injected with
the indicated viral loads of RCAS-PyMT.
C: Representative H & E stained sections of lesions found in brain, liver, and spleen of TIE2-tva mice injected with RCAS-PyMT (107 IU). All tissues examined
showed similar lesions. Scale bar 100 m.
genes (namely, vGPCR, vIRF-1, and vBCL-2), all also suspected controls infected with RCAS-vGPCR virus (107 IU) were unaf-
fected (Figure 4A).of playing an important role in spindle cell development (Bais
et al., 1998; Gao et al., 1997; Sarid et al., 1997). Surprisingly, To determine the contribution of the receptor’s constitutive
when injected in isolation, only the retrovirus expressing vGPCR signaling activity observed in vitro (Bais et al., 1998; Montaner et
affected mouse survival (Figure 3C). In contrast, necropsies al., 2001) to the phenotype observed in RCAS-vGPCR-infected
performed six months after infection of TIE2-tva mice with the animals in vivo, we prepared an inactive mutant of vGPCR con-
other candidate KSHV oncogenes revealed no gross pathology taining a 5 amino acid deletion in the carboxyl terminus,
in multiple independent trials using high viral load (107 IU). vGPCR5 (Schwarz and Murphy, 2001). Animals infected with
high titer virus (107 IU) encoding this inactive receptor (RCAS-
vGPCR5) were not affected and did not present any grossvGPCR causes multifocal KS-like tumors
Remarkably, 100% of TIE2-tva mice injected with a high viral pathology or histopathology when sacrificed up to one year
following injection (Figure 4A), suggesting that vGPCR-patho-load (107 IU) of RCAS-vGPCR virus died within six weeks of
infection (Figure 4A). Numerous microscopic tumors compro- genesis requires a persistently active receptor.
When infected with virus encoding the constitutively activemising the function of multiple organs were observed in these
animals (results not shown). In contrast, wild-type littermate vGPCR (RCAS-vGPCR) at a lower viral load (105 IU) (Figure 4A),
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Figure 3. Median survival of TIE2-tva mice follow-
ing injection with virus expressing candidate
KSHV oncogenes
A: Immunoblot of chicken fibroblasts (DF-1) trans-
fected with avian leukosis virus-derived vector
(RCAS) encoding candidate latent KSHV onco-
genes or the dominant negative p53mutV135A,
tagged with HA (vFlip), AU5 (vCyclin and
p53mutV135A), or GFP (Kaposin). The bicistronic
vCyc/vFlip construct is detectable by WB against
both AU5 (vCyclin) and HA (vFlip).
B: Infection of TIE2-tva mice with latent KSHV on-
cogenes does not impact mouse survival. Infec-
tion of EC-TVA cells in vitro with virus encoding
candidate KSHV oncogenes immunodetected
using antibody against AU5, HA, or GFP tags
(panels on left). Five-day-old mice born from
TIE2-tva  FVB/N breeding pairs were injected
with the indicated viral loads of respective virus.
C: Infection of TIE2-tva mice with other KSHV on-
cogenes. Only injection of TIE2-tva mice with vi-
rus encoding vGPCR affects mouse survival. 1To-
tal number of animals injected. 2Median survival
of either wt or tva animals injected. 3P value 	
0.01.
TIE2-tva mice survived longer but developed visible vascular man KS, the aberrant tumor vessels were composed of plump
immature endothelial cells with large nuclei encroaching thetumors in less than 4 months (Figures 4B and 4C). Necropsy
of these mice demonstrated similar lesions involving multiple vessel lumen (Figure 5G). Furthermore, the spindle-shaped tu-
mor cells displayed ovoid, often notched nuclei with finely stip-internal organs (Figures 4D–4H). Histological examination re-
vealed lesions ranging from benign angiectasias and hemangio- pled chromatin, and electron lucent cytoplasm with few organ-
elles, all common features of human KS spindle cells (Bosman etmas to solid tumors (Figure 5A), the latter composed of whorls
of spindle-shaped cells surrounded by abundant blood vessels al., 1996) (Figure 5H). Extravasated erythrocytes and occasional
erythrophagocytosis, both unique characteristics of human KSand erythrocyte-replete vascular slits (Figure 5B). The spindle-
shaped tumor cells presented diffuse infiltration of the sur- lesions, were also observed.
Immunohistochemical analysis revealed that most spindle-rounding normal tissue (Figure 5C). Notably, these cells re-
mained histologically very similar to those of nodular human KS shaped tumor cells expressed the endothelial cell markers CD31
and CD34 (Figure 6A), histological hallmarks of KS (Simonartlesions (Figures 5D and 5E). Ultrastructural analysis confirmed
that these tumors were highly vascular with tortuous vessels et al., 2000), yet failed to express other endothelial markers,
including CD54 (Figure 6A), vWF, and VE-cadherin, as well asand numerous extravasated erythrocytes (Figure 5F). Like hu-
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Figure 4. vGPCR induces multifocal angioproli-
ferative tumors in TIE2-tva mice
A: Curve shows surviving mice (%) after intraperi-
toneal injection of the indicated virus into 5-day-
old TIE2-tva mice and their littermate controls.
B–H: Lesions found in the TIE2-tva mice injected
with RCAS-vGPCR (105 IU). Representative vas-
cular tumors found in paw (B), tail (C), dermis
(D), peritoneum (E), intestine (F), heart (G), and
liver (H).
the smooth muscle cell and pericyte marker -smooth muscle macrophages (Figure 6B). Interestingly, despite the aggressive
nature of these tumors, immunohistochemical and in situ hybrid-actin (data not shown). Tumor cells were similarly negative for
TVA, suggesting loss of TIE2 promoter activity in these dediffer- ization studies of these lesions revealed that the vGPCR was
expressed in only a few tumor cells (Figure 6C), similar to theentiated cells (results not shown). Inflammatory cells were rare
within the tumor, despite the presence of frequent peritumoral vGPCR expression pattern seen in human KS lesions (Chiou et
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al., 2002). Staining was performed in both early (6 weeks) and
late (20 weeks) tumors with similar results. Thus, the gross,
histological, ultrastructural, and immunohistochemical analysis
of vGPCR-induced tumors in TIE2-tva mice strikingly resembled
that of human KS lesions. Taken together, these findings
strongly implicate vGPCR in the initiation of KS tumor develop-
ment, and further identify the endothelial cell as the probable
cell of origin of the KS spindle cell.
vGPCR promotes the tumorigenic potential of latent
KSHV genes through a paracrine mechanism
We next set out to determine the mechanism whereby vGPCR
could initiate and promote Kaposi’s sarcomagenesis, despite
being expressed in only a few tumor cells in both human KS
lesions and in our KS animal model. To this end, we prepared
endothelial cell lines stably expressing either the vGPCR (EC-
vGPCR), the individual KSHV latent genes vCyclin or vFlip (EC-
vCyclin and EC-vFlip, respectively), or both proteins vCyclin
and vFlip (EC-vCyc/vFlip) (Low et al., 2001). We took advantage
of the SV40 large T antigen immortalized murine endothelial cell
line (SVECs), as the large T antigen mimics the inhibition of p53
and Rb by the KSHV latent gene, LANA-1 (Friborg et al., 1999;
Radkov et al., 2000). Expression of the corresponding encoded
proteins for all SVEC stable cell lines was readily detected by
immunofluorescence (results not shown). When 5  105 cells
were injected subcutaneously, SVEC cells stably expressing
EGFP (EC-EGFP), similar to the parental SVEC cell line, were
unable to promote tumor formation in nude mice up to three
months following injection (Table 1). EC-vCyclin, EC-vFlip, and
the SVEC line stably expressing both latent proteins (EC-vCyc/
vFlip) were equally—albeit only weakly—able to promote tumor
formation in nude mice six weeks following injection (Table 1).
However, EC-vGPCR potently formed tumors in nude mice
within two weeks of injection, consistent with our observations
of the potency of this oncogene in the TIE2-tva model.
Interestingly, similar to studies in the TIE2-tva mice, immu-
nohistochemical analysis of the EC-vGPCR tumors revealed
that only a few cells within the tumor expressed the oncogene
(Figure 7A). vGPCR is unique among the putative KSHV onco-
genes in that it is both transforming and proangiogenic (Bais et
al., 1998). vGPCR promotes endothelial cell survival through
Akt (Montaner et al., 2001) and induces the transcription of
the potent angiogenic polypeptide vascular endothelial growth
factor (VEGF) through the activation of HIF-1 (Sodhi et al.,Figure 5. Angioproliferative tumors in vGPCR-injected TIE2-tva mice closely
resemble human KS lesions 2000, 2001). To assess the involvement of growth factor secre-
A: Examination of the liver and heart of wt and TIE2-tva (tva) animals after tion in vGPCR-mediated Kaposi’s sarcomagenesis, we investi-
injection with RCAS-vGPCR (105 IU). H & E staining reveals lesions ranging gated the levels of VEGF in the EC-vGPCR tumors. Immunohis-
from benign angiectasias (liver) to invasive solid tumors (heart). tochemical analysis of these lesions revealed that VEGF was
B and C: H & E staining of a nodular tumor in the skin. Tumor cells were
prominently expressed in a fraction of tumor cells, an expressionsurrounded by numerous blood vessels and erythrocyte-replete vascular
pattern similar to what is seen for vGPCR in these lesions (Figureslits (inset) (B). C shows the presence of spindle-shaped tumor cells (arrows)
invading adjacent muscle cells (* 
 dying muscle cells). 7A). Moreover, endothelial cells stably expressing the biologi-
D and E: H & E stained sections of a vGPCR-induced dermal tumor in a TIE2- cally inactive mutant of vGPCR, (vGPCR5), which does not
tva mouse and a human KS lesion. Spindle-shaped tumor cells (black arrows)
induce VEGF secretion (results not shown; Schwarz and Mur-exhibit large nuclei, prominent nucleoli, and occasional mitoses (white
phy, 2001), were unable to form tumors when injected in nudearrows) (D), which closely resemble spindle cells of human KS lesions (E).
F: Scanning electron microscopy of nodular tumor. Tumor vasculature (*) mice (Table 1).
was highly tortuous, with numerous extravasated red blood cells (white Based on these results, we hypothesized that the ability of
arrow). vGPCR to form tumors may require the paracrine recruitmentG and H: Transmission electron microscopy of tumor. Endothelial cells of
and transformation of neighboring cells. To test this hypothesis,aberrant tumor vessels were immature, with large nuclei encroaching vessel
lumen (G). H shows typical tumor spindle cell with notched nucleus (*), few nude mice were injected with mixed cell populations in which
organelles, and erythrophagocytosis (white arrows). only a small fraction of cells (10%) were expressing the vGPCR,
A–F: Scale bar 50 m; G and H: original magnification, 3000. similar to the expression pattern of this gene in human KS
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Figure 6. Immunohistochemical characterization of the angioproliferative tumors induced by the vGPCR in TIE2-tva mice
A: Staining with CD31 (PECAM-1) and CD34 specific antibodies shows expression both in vascular endothelial cells and tumor cells. CD54 (ICAM-1) was
negative in tumor cells.
B: Immunodetection of macrophages (tumor, left; peritumor, right), B cells, and T cells in tumor sections, using F4/80, CD45R/B220, and CD3 antibodies,
respectively. Scale bar 50 m.
C: Representative section stained with anti-AU5 antibody or hybridized to labeled anti-sense probe for vGPCR (inset, darkfield) showing expression and
transcription of the vGPCR in only few tumor cells.
lesions (Chiou et al., 2002). As shown in Table 1, when a low KSHV-infected KS tumor cells (90%) but are not tumorigenic
in the TIE2-tva mouse model or when expressed in SVEC cells,number of EC-vGPCR (5  104 cells) was injected subcutane-
ously into nude mice, they only rarely (	10% of injected animals) may however manifest their transforming potential in the context
of the paracrine secretions of vGPCR-expressing cells. As anformed small tumors, and only after two months following injec-
tion. As mentioned above, injection of a high number of EC- approach, we next injected a low number of EC-vGPCR (5 
104 cells) mixed with EC-vFLIP or EC-vCyclin (5  105) cells.EGFP (5  105 cells) alone was unable to form tumors. Surpris-
ingly, injection of a mixed endothelial cell population of both Both EC-vFlip and EC-vCyclin were able to form visible tumors
within one month when injected with EC-vGPCR, similar to thatthe low amounts of EC-vGPCR (5  104 cells) with EC-EGFP
(5  105 cells) was able to form visible tumors as early as one observed when the EC-vGPCR cells were mixed with EC-EGFP
cells. However, injection of EC-vCyc/vFlip cells (5  105 cells)month following injection in over 50% of injected animals (Table
1), suggesting that vGPCR-expressing endothelial cells are able with EC-vGPCR cells (5  104 cells) formed tumors in 100% of
the animals within only two weeks of injection (Table 1). Of note,to rescue the normally nontransforming EC-EGFP cells. Indeed,
immunohistochemical analysis of tumors formed by this mixed these tumors were much larger and grew more rapidly than
those formed by the mixed populations of the EC-vGPCR withendothelial cell population revealed a heterogeneous cell popu-
lation, expressing either the vGPCR or EGFP (Figure 7B). endothelial cells stably expressing vFlip or vCyclin alone. To
confirm the contribution of EC-vCyc/vFlip cells to these lesions,These observations prompted us to examine whether the
latent KSHV genes, which are expressed by the majority of we also examined expression of the HA-tagged vFlip protein in
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yet retained expression of several, but not all, endothelial mark-Table 1. Tumorigenesis of SVEC stable cell lines
ers, similar to human KS lesions (Simonart et al., 2000). In addi-
SVEC line Number of cells n1 Tumors2 tion to their remarkable histological and ultrastructural similarity
EC-EGFP 5  105 20  to human KS lesions, vGPCR-induced tumors had a unique
EC-vGPCR 5  105 20  predilection for the dermis, similar to human KS. This is in strik-
EC-vGPCR5 5  105 20 
ing contrast to other oncogenes introduced into TIE2-tva miceEC-vCyclin 5  105 10 
(e.g., polyoma middle T antigen), which did not form visible skinEC-vFlip 5  105 10 
EC-vCyc/vFlip 5  105 10  lesions in multiple independent trials, despite a potent ability to
EC-vGPCR 5  104 10 / form endothelial tumors in almost all other tissues examined
EC-vGPCR  EC-EGFP 5  104 (results not shown). These results suggest that dermal endothe-5  105 10 
lial cells may be particularly vulnerable to vGPCR-inducedEC-vGPCR  EC-vCyclin 5  104
5  105 10  Kaposi’s sarcomagenesis, perhaps explaining why systemic in-
EC-vGPCR  EC-vFlip 5  104 fection with KSHV often manifests only with dermal KS lesions.
5  105 10  This compelling congruence between vGPCR-induced tumors
EC-vGPCR  EC-vCyc/vFlip 5  104
and human Kaposi’s sarcoma suggests the importance of ex-5  105 10 
ploring vGPCR oncogenesis to fully understand KSHV patho-EC-vGPCR5 EC-vCyc/vFlip 5  104
5  105 10  genesis.
Of note, expression of the vGPCR in T-cells has been shown6-week-old female Nu/Nu mice were injected subcutaneously (SQ) with
SVECs stably expressing candidate KSHV oncogenes. to produce tumors in transgenic mice (Yang et al., 2000). How-
1 Total number of animals injected. ever, this observed phenotype may have resulted from the accu-
2 Tumor formation 6 weeks following injection; tumorigenic potential was mulation of genetic changes induced by the persistent expres-
quantitated as follows: no tumors (); tumors in less than 25% of mice in-
sion of the vGPCR in lymphoid cells during development, ajected, 	25 mg (); tumors in 25%–75% of mice injected, 25–50 mg ();
process unlikely to play a role in Kaposi’s sarcomagenesis. Thetumors in 75%–100% of mice injected, 50–100 mg (); tumors in 75%–100%
of mice injected, 100–150 mg (); tumors in 75%–100% of mice injected, TIE2-tva model may reflect better the function of this receptor
150 mg (). in KS, as it recreates more faithfully the in vivo infectious process
by which KSHV infects a limited number of cells of endothelial
origin (Flore et al., 1998).
Indeed, in our model, similar to human KS, few of these
tumor cells expressed the vGPCR (Chiou et al., 2002). ThisEC-vGPCR  EC-vCyc/vFlip mixed cell tumors. Immunohisto-
suggests that receptor expression may be lost once the cellschemical analysis revealed that most cells were indeed derived
are transformed and the receptor is no longer needed for cellfrom the EC-vCyc/vFlip cell line (Figure 7C), an expression pat-
survival. However, we cannot rule out the possibility that ex-tern similar to what is seen in human KS lesions (Gruffat et al.,
pression of this GPCR in our KS model—and in human KS—2000).
may be at such low levels that its detection may be limited byIn addition to its role in the initiation of KS tumors, these
the inherent sensitivity of the techniques used. Alternatively,results strongly suggest that the vGPCR may also participate
vGPCR-expressing cells may promote the recruitment, hyper-in KS tumor progression by unmasking the tumorigenic potential
proliferation, and subsequent transformation of adjacent cellsof latent KSHV genes. Investigation of VEGF levels in the EC-
through the secretion of multiple cytokines and potent polypep-vGPCR  EC-vCyc/vFlip mixed cell tumors revealed that VEGF
tide growth factors (Bais et al., 1998; Couty et al., 2001; Patiwas again only expressed in a fraction of tumor cells (Figure 7C).
et al., 2001; Schwarz and Murphy, 2001; Sodhi et al., 2000).Conversely, endothelial cells stably expressing the biologically
The ability of the receptor to cause endothelial cell survival ininactive mutant of vGPCR, vGPCR5, were not tumorigenic
vitro (Montaner et al., 2001) and the release of growth factorsand did not promote tumor formation when injected at low
and cytokines from vGPCR-expressing cells (Bais et al., 1998;concentration (5  104 cells) together with EC-vCyc/vFlip (5 
Pati et al., 2001; Schwarz and Murphy, 2001; Sodhi et al., 2000)105 cells) (Table 1), suggestive of a requirement for constitutive
argue in favor of a role for vGPCR in both direct transformationactivity for vGPCR pathogenesis. Collectively, these results
and in paracrine recruitment. Indeed, cells expressing thestrongly suggest that vGPCR recruits and transforms latently
vGPCR express elevated levels of the angiogenic growth factorsinfected endothelial cells through a paracrine mechanism involv-
including VEGF (results not shown, Bais et al., 1998). Further-ing the secretion of angiogenic growth factors, such as VEGF,
more, media conditioned by vGPCR-expressing cells promotesand further identify this viral oncogene as a key target for the
the growth and proliferation of endothelial cells (results notdevelopment of pathogenesis-based therapies against KSHV.
shown; Bais et al., 1998). We also show here that endothelial
cells stably expressing vGPCR can unmask the tumorigenicDiscussion
potential of KSHV latent genes, suggestive of a cooperative role
between vGPCR and viral latent genes in KS tumor progression.We engineered transgenic animals expressing the avian retrovi-
In the context of the TIE2-tva model, none of the other KSHVral receptor, TVA, under the TIE2 promoter, to enable endothelial
genes tested was able to cause a biological effect, in spite ofcell-specific infection with avian leukosis virus expressing KSHV
evidence that several of them can transform cell lines in vitro.genes believed to play a role in spindle cell growth and survival.
The corresponding encoded proteins of all ALV-derived viralTIE2-tva mice infected with the KSHV gene, vGPCR, developed
constructs were readily detected by immunodetection in murinevascular tumors that closely resembled human KS lesions and
endothelial cells (ectopically expressing TVA) infected in vitro.expressed key histopathological and molecular hallmarks for
this disease. Spindle-shaped tumor cells were dedifferentiated, However, due to the limited number of endothelial cells infected
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Figure 7. Immunohistochemical characterization of the allograft tumors formed by mixed population of SVEC stable cell lines in nude mice
A: Left, representative section of tumor formed by 5  105 EC-vGPCR cells stained with anti-AU5 antibody showing rare vGPCR-expressing cells (black
arrows). Right, EC-vGPCR tumor stained with anti-VEGF antibody showing expression of VEGF in few tumor cells, an expression pattern similar to that seen
for vGPCR-expressing cells.
B: Left, tumor formed by mixed cell population of 5  104 EC-vGPCR with 5  105 EC-EGFP stained with anti-AU5 antibody showing rare vGPCR-expressing
cells (black arrows). Right, staining with EGFP specific antibody shows expression of GFP in many tumor cells. Inset, EGFP expression in EC-vGPCR tumors
(A) was negative.
C: Left, representative section of tumor formed by mixed cell population of 5  104 EC-vGPCR mixed with 5  105 EC-vCyc/vFlip stained with anti-HA
antibody showing characteristic punctate expression of HA-vFlip in most tumor cells. Right, tumor formed by EC-vGPCR  EC-vCyc/vFlip stained with anti-
VEGF antibody showing expression of VEGF in few tumor cells, an expression pattern similar to that seen in A in EC-vGPCR tumors. Scale bar 50 m.
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in TIE2-tva mice, we could not confirm the expression of the vitro data on the vGPCR has revealed that this receptor signals
through multiple intracellular regulatory pathways (Bais et al.,latent genes in vivo. Consequently, we cannot rule out the possi-
bility that the level of gene expression in the TIE2-tva model 1998; Couty et al., 2001; Montaner et al., 2001; Pati et al., 2001;
Sodhi et al., 2000). As GPCRs have proven to be effective targetswas insufficient for the animals to manifest an overt phenotype.
Nonetheless, these results suggest that infection of endothelial for pharmacological intervention (Marinissen and Gutkind,
2001), our findings thus suggest that the vGPCR and its down-cells with individual KSHV latent genes alone may not be suffi-
cient for transformation in vivo. Rather, these genes may coop- stream signaling routes may represent ideal targets for the de-
velopment of pathogenesis-based therapies against KSHV. Inerate with the vGPCR and with each other, or may further require
HIV-1 genes (e.g., tat) (Barillari and Ensoli, 2002) in the context this regard, our animal model may now help elucidate the biolog-
ical significance of the intervening signaling molecules in theof an immunosuppressed host to exhibit their transforming po-
tential. Since multiple genes may be delivered to the same development of KS and may further identify effective treatments
for this elusive disease. Ultimately, the TIE2-tva model may beendothelial cells of TIE2-tva mice, this mouse model will be
ideally suited to address this complex interplay among KSHV similarly exploited in the context of many other diseases that
are also known to involve the aberrant function of endothelialgenes, as well as the contribution of HIV-1 and immunosuppres-
sion to KSHV oncogenesis. cells, as it enables examination of the biological outcome of
expressing specific genes of interest in endothelial cells in vivo,The vGPCR has been designated as a lytic gene based on
in vitro experiments using chemicals to induce expression from using a single transgenic animal.
virally infected B cells from a primary effusion lymphoma (PEL)
Experimental procedurescell line (Sun et al., 1999). However, these studies may not define
the events that occur early in the in vivo infectious process, and
Mouse strains
may not be predictive of the ability of these viral genes to initiate The TIE2-tva transgene was generated by insertion of the pg800 tva cDNA
host cell transformation. Moreover, as few individuals infected (Bates et al., 1993; Young et al., 1993) as a NotI fragment into a bluescript
by KSHV go on to manifest Kaposi’s sarcoma, it is likely that SK () vector containing the murine 2.1 kb HindIII TIE2 promoter fragment
and SV40 poly (A) signal sequence. The plasmid also included, downstreamderegulation of normal viral gene expression programs may play
of the tva cassette, a 10 kb autonomous endothelial-specific enhancer lo-a fundamental role in the development of this disease. Thus,
cated in the first intron of the mouse TIE2 gene, which allows specific andKSHV genes that are not normally expressed during the latent
uniform gene expression to all vascular ECs in vivo (Schlaeger et al., 1997).
cycle may still play an important role in the initiation of Kaposi’s The TIE2-tva insert was isolated after digestion by SalI. Transgenic mice
sarcoma. In this regard, recent findings suggest that infection were generated in FVB/N mice using standard techniques and identified by
with HIV-1 upregulates expression of KSHV lytic genes (Vartha- Southern blot using the tva cDNA as a probe. Genotypes were determined
by Southern blotting and by PCR with tail DNA. The athymic (nu/nu) nudekavi et al., 2002). Within this framework, we envision that the
females were purchased from Harlan Sprague Dawley.viral GPCR may serve as a transforming gene upon deregulated
expression, as occurs with HIV infection. Indeed, AIDS-KS le-
Viral constructssions show increased expression of vGPCR and are significantly
The KHSV genome was obtained from NIH AIDS Research & Reference
more aggressive than classic KS lesions (Yen-Moore et al., Reagent Program and open reading frames encoding for v-Cyclin (ORF72),
2000). Kaposin (K12), vIRF1 (K9), vFLIP (ORF71), vBcl2 (ORF 16), vGPCR (ORF74),
and both v-Cyclin and vFlip (bicistronic construct) were cloned by PCRAlternatively, the vGPCR may initiate cell transformation
based on their published sequences (Low et al., 2001; Russo et al., 1996).when expressed transiently, early in the infectious process. The
The vGPCR5 mutant (deletion of carboxyl terminal amino acids 338 to 342)expression of this receptor may then create an environment in
was obtained by PCR using a 3 oligo encoding amino acids 332 to 337which subsequent tumor development can occur in the pres-
followed by a stop codon and a Not I site. The dominant negative p53 mutant
ence of other KSHV survival genes, after which receptor expres- V135A was obtained from Clontech. cDNA encoding for an intracellular form
sion may become unnecessary (Cesarman et al., 2000). This of the -lactamase enzyme was obtained by PCR using pGEX 4T-3 as a
“hit-and-run” mechanism is certainly not without precedent. It template. To prepare the viral constructs, cDNAs were subcloned into
pCEFL-HA, pCEFL-AU5, or pCEFL-EGFP to generate epitope-tagged formshas been extensively documented for the major transforming
of these gene products, and then transferred into the RCAS vector. Theprotein of the human T cell leukemia virus-1 (HTLV-1), Tax,
polyomavirus middle T antigen from RCAS-PyMT (Holland et al., 2000) waswhich is only expressed in early stages of tumor formation and is
tagged by cloning into pCEFL-AU5, and then subcloned again into RCAS.
not required in established T cell malignancies (Yoshida, 2001). RCAS-AP, encoding the heat-resistant placental alkaline phosphatase has
Similarly, papilloma virus E5 also appears to play a critical role been previously described (Federspiel et al., 1994).
in cell transformation early in infection, and yet is rarely detected
Cell lines and transfectionsonce tumors are formed (DiMaio and Mattoon, 2001). For the
SV-40 immortalized murine endothelial cells (SVECs) were grown in Dulbec-vGPCR, expression of the receptor during the viral lytic cycle
co’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovinemay also be important in sustaining tumor growth through a
serum (FBS) and 1% penicillin/streptomycin. Transfection of SVECs wasparacrine mechanism, as supported by our results demonstra-
performed using Fugene Reagent (Roche Applied Science). SVEC cells ex-
ting that the vGPCR can unmask the tumorigenic potential of pressing TVA, EGFP, or KSHV genes were obtained by stable transfection
latent KSHV genes through the secretion of angiogenic growth of the corresponding pCEFL-derived plasmids (EC-lines). DF-1 chicken fi-
broblasts were maintained in DMEM with high glucose, supplemented withfactors including VEGF. This is further supported by recent evi-
10% FBS and 1% penicillin/streptomycin. DF-1 cells were transfected usingdence demonstrating that interruption of lytic replication can
Superfect reagent (Qiagen).impair KS tumor development at all stages of the natural history
of KSHV infection (Martin et al., 1999).
Preparation of virus and infection of transgenic mice
Taken together, these data and our present findings strongly DF-1 cells were transfected with RCAS vectors to produce recombinant
suggest that the vGPCR is likely to play a critical role in both the viruses. After several days of passage in culture, cell-free viral supernatants
were ultracentrifuged in an SW28 Beckman rotor at 22,000 rpm at 4C forinitiation and promotion of KS tumor development. Of interest, in
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two hours. Pellets were resuspended in 1/100 of the original volume and scanning electron microscope equipped with a PGT-IMIX-PC EDS system.
viral titers were determined by limiting dilution. Briefly, EC-TVA cells were Transmission electron microscopy (TEM) was performed by using a JEOL
seeded into 6-well culture dishes at 30% confluence and infected with serial 100-CXII.
10-fold dilutions of concentrated viral supernatants in growth medium. The
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